Journal
LEUKEMIA & LYMPHOMA
Volume 63, Issue 10, Pages 2413-2421Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2022.2068001
Keywords
Proteasome inhibitors; newly diagnosed multiple myeloma; clinical trials
Categories
Funding
- Amgen Inc.
Ask authors/readers for more resources
This pooled analysis of four studies evaluated the clinical effectiveness of KRd in newly diagnosed multiple myeloma patients. The results showed that KRd is an effective and tolerable treatment option for patients regardless of autologous stem cell transplant eligibility.
Pooled analyses of four single-arm phase 1 and 2 studies (NCT01816971, NCT02405364, NCT01029054, NCT01402284) investigated the clinical effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd) in newly diagnosed multiple myeloma (NDMM). Patients who did (Cohort 1; n = 122) and did not (Cohort 2; n = 99) undergo autologous stem cell transplant (high-dose melphalan [HDM]-ASCT) were included. Patients received a 28-day cycle of induction KRd. The rate of very good partial response or better, the primary endpoint, was 93% in Cohort 1 and 90% in Cohort 2. Two-year progression-free survival and overall survival rates were 88% and 96% for Cohort 1, and 85% and 97% for Cohort 2. At least 90% of patients in each cohort reported >= 1 grade 3 or 4 treatment-emergent adverse events. Subgroup analyses by age, International Staging System stage, and cytogenetic risk were consistent with the overall population. KRd is an effective and tolerable treatment option for patients with NDMM regardless of HDM-ASCT eligibility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available